← Back to Search

6D-MRI Predictive Imaging for Pancreatic Cancer

N/A

Recruiting

Led By Stephen Pandol, MD

Research Sponsored by Cedars-Sinai Medical Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Pancreatic cancer patients (with resectable or borderline resectable or locally advanced tumors) who will undergo neoadjuvant chemotherapy

Be older than 18 years old

Must not have

Patients with metastatic pancreatic cancer visualized on index diagnostic imaging

Patients who have previously been treated for PDAC

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 2 years

Awards & highlights

No Placebo-Only Group

Summary

This trial will test if 6D-MRI can help predict outcomes for pancreatic cancer patients.

Who is the study for?

This trial is for pancreatic cancer patients who can have at least two MRI sessions and are about to start chemotherapy. They must be able to sync a device with Fitbit or use someone else's. It's not for those with severe claustrophobia, previous PDAC treatments, metastatic cancer seen on initial scans, or certain metal implants.

What is being tested?

The study is testing if a new type of MRI called 6D-MRI can predict how well patients with pancreatic ductal adenocarcinoma will respond to treatment before they begin their chemotherapy regimen.

What are the potential side effects?

Since the intervention involves only MRI scanning, side effects may include discomfort from lying still during the procedure and potential anxiety in the machine. There might also be risks related to contrast agents used during MRIs.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have pancreatic cancer and will receive chemotherapy before surgery.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

My pancreatic cancer has spread and can be seen on scans.

Select...

I have been treated for pancreatic cancer before.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Change in functional status from baseline, as measured by the Eastern Cooperative Oncology Group (ECOG) Scale of Performance Status

Change in overall health from baseline, as measured by the Charlson Comorbidity Index (CCI)

Number of participants with R0 resection

+1 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: 6D-MRIExperimental Treatment1 Intervention

Participants will undergo 6D-MRI imaging three times throughout the course of the study: once pre-NAT treatment, once during NAT treatment, and once post-NAT treatment.

0 / 3Eligibility criteria met